Food and Drug Administration - February 9, 2012
The U.S. Food and Drug Administration (FDA) is notifying
healthcare professionals and patients that drug interactions
between the hepatitis C virus (HCV) protease inhibitor Victrelis
(boceprevir) and certain ritonavir-boosted human immunodeficiency
virus (HIV) protease inhibitors (atazanavir, lopinavir,
darunavir) can potentially reduce the effectiveness of these
medicines when they are used together.